Cargando…

Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma

Durvalumab is an anti‐PD‐L1 monoclonal antibody approved for patients with locally advanced or metastatic urothelial carcinoma (UC) that has progressed after platinum‐containing chemotherapy. A population tumor kinetic model, coupled with dropout and survival models, was developed to describe longit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Yanan, Narwal, Rajesh, Jin, ChaoYu, Baverel, Paul G., Jin, Xiaoping, Gupta, Ashok, Ben, Yong, Wang, Bing, Mukhopadhyay, Pralay, Higgs, Brandon W., Roskos, Lorin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873369/ https://www.ncbi.nlm.nih.gov/pubmed/29243222 http://dx.doi.org/10.1002/cpt.986

Ejemplares similares

Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
por: Baverel, Paul G., et al.
Publicado: (2018)

Optimal PD-L1–high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy
por: Zajac, Magdalena, et al.
Publicado: (2020)

Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status
por: Baverel, Paul, et al.
Publicado: (2019)

Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma
por: Arends, Rosalinda, et al.
Publicado: (2021)

Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
por: Narwal, Rajesh, et al.
Publicado: (2013)

A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition
por: Gong, Chang, et al.
Publicado: (2017)

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
por: Alt, Marie, et al.
Publicado: (2023)

Durvalumab for urothelial carcinoma, non-small cell lung cancer
Publicado: (2019)

A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
por: Jafarnejad, Mohammad, et al.
Publicado: (2019)

A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade
por: Milberg, Oleg, et al.
Publicado: (2019)

Quantitative Measurement of the Target-Mediated Internalization Kinetics of Biopharmaceuticals
por: Vainshtein, Inna, et al.
Publicado: (2014)

In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model
por: Wang, Hanwen, et al.
Publicado: (2019)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
por: Sheth, Siddharth, et al.
Publicado: (2020)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
por: Faiena, Izak, et al.
Publicado: (2018)

Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential
por: Baldini, Capucine, et al.
Publicado: (2019)

Curative-Intent Treatment with Durvalumab in Early-Stage Cancers
por: Melillo, Giovanni, et al.
Publicado: (2021)

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract
por: Sarfaty, Michal, et al.
Publicado: (2020)

Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023
por: Joshi, Monika, et al.
Publicado: (2023)

Model‐Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab
por: Wang, Bing, et al.
Publicado: (2017)

Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer
por: Kim, Eun Young, et al.
Publicado: (2019)

Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis
por: Guo, Xiang, et al.
Publicado: (2014)

Mechanistic modeling of a human IgG(4) monoclonal antibody (tralokinumab) Fab‐arm exchange with endogenous IgG(4) in healthy volunteers
por: Wang, Bing, et al.
Publicado: (2022)

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
por: Gray, Jhanelle E., et al.
Publicado: (2019)

Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
por: Ouwens, Mario J. N. M., et al.
Publicado: (2019)

Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma
por: Yan, Li, et al.
Publicado: (2019)

Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis
por: Ye, Jiabu, et al.
Publicado: (2020)

Durvalumab: First Global Approval
por: Syed, Yahiya Y.
Publicado: (2017)

Retinal Vasculitis Secondary to Durvalumab
por: R. Andrade, Antonio, et al.
Publicado: (2020)

Durvalumab-induced Severe Gastritis
por: Otohara, Masaya, et al.
Publicado: (2021)

Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study
por: Ouwens, Mario, et al.
Publicado: (2021)

Incidental Diagnosis of Urothelial Bladder Cancer: Associations with Overall Survival
por: Kamecki, Hubert, et al.
Publicado: (2023)

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
por: Rosenberg, Jonathan E., et al.
Publicado: (2023)

Minimal Change Disease Associated With Durvalumab
por: Toda, Masataro G., et al.
Publicado: (2021)

The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer
por: Matsuura, Shun, et al.
Publicado: (2023)

Durvalumab in NSCLC: latest evidence and clinical potential
por: Muñoz-Unceta, Nerea, et al.
Publicado: (2018)

Phimosis: A rare complication of immunotherapy with durvalumab
por: Vázquez-Lavista, Luis Gabriel, et al.
Publicado: (2020)

Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism
por: Patel, Shivani, et al.
Publicado: (2019)

Durvalumab induced sarcoid‐like pulmonary lymphadenopathy
por: Sanderson, Emma, et al.
Publicado: (2020)

Acquired amegakaryocytic thrombocytopenia after durvalumab administration
por: Suyama, Takahiro, et al.
Publicado: (2021)

Durvalumab: Immune-related pneumonitis: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tvrdla5qailrhlmculukdt1kue